{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:08:19Z","timestamp":1795090099625,"version":"4.10.2"},"reference-count":26,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Fludarabine (FLU) is used for lymphodepletion and improves the persistence and expansion of chimeric antigen receptor (CAR) T cells in vivo. Higher FLU systemic exposure is associated with lower relapse risk and improved leukemia-free survival in pediatric patients with acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy. FLU pharmacokinetics (PKs) is age dependent, with increased clearance in younger children. Here, we used modeling and simulation, including clinical trial simulations, to define age-adjusted FLU dosage regimens that may maintain effective FLU exposures and improve outcomes. The FLU PK and pharmacodynamic relationships with overall survival (OS) and cumulative incidence of relapse (CIR) were derived from published pediatric populations. Four FLU dosages were considered for the simulations: 75 or 120 mg\/m2 cumulative fixed dose, age-adjusted dosing, and doses based on therapeutic drug monitoring (TDM). The target FLU cumulative area under the curve range was defined as 13.8 to 25 mg \u00d7 h\/L. Clinical trial simulations showed that across the pediatric age range, the number of individuals in the target range increased from a median of 22% to 61% with fixed dosages, to 72% with age-adjusted dosing and 94% with TDM. Clinical trial simulations also showed that age-adjusted or TDM dosing could increase the median number of individuals with OS at 24 months by 67% and decrease the median number of individuals with CIR at 12 months by 72%, compared with fixed dosages. In conclusion, these simulation studies support using FLU age-adjusted or TDM dosing to increase the number of individuals achieving exposure within the targeted range and, therefore, improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015928","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T16:44:14Z","timestamp":1751561054000},"page":"4676-4682","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-7208","authenticated-orcid":false,"given":"John C.","family":"Panetta","sequence":"first","affiliation":[{"name":"1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-6706","authenticated-orcid":false,"given":"Aimee C.","family":"Talleur","sequence":"additional","affiliation":[{"name":"2Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-7360","authenticated-orcid":false,"given":"Swati","family":"Naik","sequence":"additional","affiliation":[{"name":"2Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[{"name":"2Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-4533","authenticated-orcid":false,"given":"Markos","family":"Leggas","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"5","key":"2025092310170208200_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2025092310170208200_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus Med Rev"},{"issue":"1","key":"2025092310170208200_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J Immunother"},{"issue":"12","key":"2025092310170208200_bib4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"7","key":"2025092310170208200_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"2","key":"2025092310170208200_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"issue":"26","key":"2025092310170208200_bib7","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2025092310170208200_bib8","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2025092310170208200_bib9","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2025092310170208200_bib10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2025092310170208200_bib11","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025092310170208200_bib12","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025092310170208200_bib13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/17474086.2016.1203251","article-title":"Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape","volume":"9","author":"Turtle","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"23","key":"2025092310170208200_bib14","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1182\/blood.V126.23.4426.4426","article-title":"Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy","volume":"126","author":"Bot","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2025092310170208200_bib15","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2025092310170208200_bib16","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"18","key":"2025092310170208200_bib17","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","article-title":"Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2025092310170208200_bib18","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bbmt.2017.06.021","article-title":"Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients","volume":"23","author":"Ivaturi","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"14","key":"2025092310170208200_bib19","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2025092310170208200_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bmt.2010.53","article-title":"High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation","volume":"46","author":"Long-Boyle","year":"2011","journal-title":"Bone Marrow Transpl"},{"key":"2025092310170208200_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.trsl.2016.03.017","article-title":"Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning","volume":"175","author":"Sanghavi","year":"2016","journal-title":"Transl Res"},{"issue":"5","key":"2025092310170208200_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-018-0715-9","article-title":"Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation","volume":"58","author":"Langenhorst","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2025092310170208200_bib23","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics\n          . CDC Growth Charts Data Files. 2024. Accessed 16 July 2025. https:\/\/www.cdc.gov\/growthcharts\/cdc-data-files.htm."},{"issue":"2","key":"2025092310170208200_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/1078-0432.CCR-0844-03","article-title":"Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma","volume":"10","author":"Yule","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025092310170208200_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270008325928","article-title":"Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group","volume":"49","author":"McCune","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"2025092310170208200_bib26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1078-0432.CCR-19-2685","article-title":"Exposure-toxicity association of cyclophosphamide and its metabolites in infants and young children with primary brain tumors: implications for dosing","volume":"26","author":"Campagne","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4676\/2412325\/blooda_adv-2025-015928-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/18\/4676\/2412325\/blooda_adv-2025-015928-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:34:39Z","timestamp":1758638079000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/18\/4676\/546047\/Age-adjusted-dosing-of-fludarabine-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":26,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015928","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,23]]},"published":{"date-parts":[[2025,9,12]]}}}